Dapagliflozin: Potential Role in Pediatric Cardiac Patient Care

Cardiol Rev. 2026 May 11. doi: 10.1097/CRD.0000000000001290. Online ahead of print.ABSTRACTSodium-glucose cotransporter 2 inhibitors have demonstrated substantial cardiovascular and renal benefits in adults, including reduced heart failure events across diabetic and nondiabetic populations. However,

K Karim Bitar

Finerenone and Empagliflozin in Type 2 Diabetes

Cardiol Rev. 2026 May 11. doi: 10.1097/CRD.0000000000001308. Online ahead of print.ABSTRACTCardiovascular disease and chronic kidney disease remain the leading causes of morbidity and mortality in patients with type 2 diabetes, even when conventional risk factors are well managed. Two drug classes h

M Muhammad Abdullah

Designing genome editing experiments with EditABLE

Genome Biol. 2026 May 11. doi: 10.1186/s13059-026-04095-x. Online ahead of print.ABSTRACTWhile many computational tools exist for designing CRISPR-Cas experiments, there is a need for a centralized resource that combines individual tools to predict the most efficient genome editing strategy for a gi

D Demetrios S Maxim